Yeji Kim

Yeji Kim

Auto-generated profile, based on publicly available information

Yeji Kim

NYU Langone Health 7 Department of Population Health, New York University School of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Biometrical Journal
Verified
Journal Article
Open access
YKYeji Kim
Yeji Kim
TCTaehwa Choi
Taehwa Choi
SPSeohyeon Park
Seohyeon Park
SCSangbum Choi
Sangbum Choi
DBDipankar Bandyopadhyay
Dipankar Bandyopadhyay
This paper introduces a novel approach to estimating censored quantile regression using inverse probability of censoring weighted (IPCW) methodology, specifically tailored for data sets featuring partially interval‐censored data. Such data sets, often encountered in HIV/AIDS and cancer biomedical research, may include doubly censored (DC) and partly interval‐censored (PIC) endpoints. DC responses involve either left‐censoring or right‐censoring alongside some exact failure time observations, while PIC responses are subject to interval‐censoring. Despite the existence of complex estimating techniques for interval‐censored quantile regression, we propose a simple and intuitive IPCW‐based method, easily implementable by assigning suitable inverse‐probability weights to subjects with exact failure time observations. The resulting estimator exhibits asymptotic properties, such as uniform consistency and weak convergence, and we explore an augmented‐IPCW (AIPCW) approach to enhance efficiency. In addition, our method can be adapted for multivariate partially interval‐censored data. Simulation studies demonstrate the new procedure's strong finite‐sample performance. We illustrate the practical application of our approach through an analysis of progression‐free survival endpoints in a phase III clinical trial focusing on metastatic colorectal cancer.

12 November 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
FDFares Darawshy
Fares Darawshy
JTJun-Chieh J. Tsay
Jun-Chieh J. Tsay
ESElizabeth Sanchez
Elizabeth Sanchez
DJDong-Min Jin
Dong-Min Jin
YKYeji Kim
Yeji Kim
LSLeopoldo N. Segal
Leopoldo N. Segal
Immune checkpoint inhibitors (ICI) have transformed the treatment of advanced non–small cell lung cancer (NSCLC), yet a large proportion of patients do not respond. The lung microbiome is a key modulator of antitumor immunity; however, the functional contribution of active microbial communities and their interaction with host transcriptional programs in shaping ICI outcomes remain poorly defined. In this study, we prospectively analyzed bronchoalveolar lavage (BAL) samples from 71 patients with NSCLC prior to ICI initiation. We profiled the microbiome and host transcriptome in the BAL to look for microbial and host signatures in the lower airways associated with treatment response. We found that enrichment of the lower airway microbiome with oral commensals was associated with disease progression and worse prognosis of patients treated with ICIs. Metatranscriptomics-derived microbial clustering revealed distinct functional profiles. The microbial cluster enriched with oral commensals, which was only present among patients with poor response to ICIs, had differential regulation of pathways involved in the metabolism of short-chain fatty acids, methane, and pyruvate. This cluster also correlated with host immune pathways including upregulation of interferon signaling, neutrophil degranulation, and mitophagy, all of which could contribute to the poor response to immunotherapy. In a preclinical murine model of lung cancer with dysbiosis, inoculating lung tumor–bearing mice with oral commensals increased intratumoral neutrophils and Th17 responses and impaired ICI efficacy. Our findings support the concept that microbial communities in the lower airways influence tumor–immune interactions via defined metabolic–immune axes. Significance: Transcriptionally active lower airway microbial communities are linked clinically and preclinically to immunotherapy response in NSCLC, identifying microbial activity as a functional interface with the tumor microenvironment and a potential therapeutic target.

1 January 2019 in Journal of the Korean Ophthalmological Society
Verified
Journal Article
Open access
PDF file
YKYeji Kim
Yeji Kim
YHYoung Hoon Hwang
Young Hoon Hwang
Kim Y, et al. J Korean Ophthalmol Soc. 2019 Sep;60(9):874-880. https://doi.org/10.3341/jkos.2019.60.9.874